Global 
Deutschland 
Editorial
Dear colleagues,
In medicine, it is always particularly stimulating when long-established dogmata and treatment algorithms are critically reexamined and revised. Two studies featured in this issue exemplify this.
The BOSS trial by Old et al. challenges established surveillance strategies for Barrett’s esophagus. In this randomized trial, 3453 patients with Barrett’s esophagus were assigned to either 2-yearly surveillance endoscopy or endoscopy performed only when clinically indicated by symptoms. Over a minimum follow-up period of 10 years, no differences were observed in overall survival or cancer-specific survival between both groups. An accompanying health economic analysis further demonstrated that routine endoscopic surveillance, as practiced to date, is not cost-effective. […]
In recent years, several pivotal studies demonstrated the efficacy of immune checkpoint inhibitors in the treatment of gastrointestinal cancer. In colorectal cancer, immunotherapy has shown particularly impressive results in tumors characterized by high microsatellite instability or mismatch repair deficiency (dMMR). The STELLAR-303 trial, a phase 3 trial in patients with advanced colorectal cancer without microsatellite instability-high or dMMR tumors (Hecht et al.), now provides first evidence that an immunotherapy-based regimen with zanzalitinib and atezolizumab allows somewhat better overall survival compared with regorafenib. These results prompt renewed discussion about the potential role of immunotherapy-based approaches for the broader treatment landscape of colorectal cancer in the future.
Beginning with this issue, and alongside our established critical expert opinions, we are introducing a new feature in which 10 selected publications are highlighted as Editors’ Choice as shown below. This designation is intended to help readers more readily to identify articles of particular relevance and interest within each issue. Further developments and new content can be expected in forthcoming editions.
We hope you will find the articles in this issue both informative and inspiring.
Yours sincerely,
Peter Hasselblatt and Tobias Böttler
Department of Internal Medicine II, University Medical Center Freiburg (Germany)
Current literature articles in this edition
Efficacy and safety of time-restricted eating in metabolic dysfunction-associated steatotic liver disease
J Hepatol. 2025;83(6):1256-1265
Claudin-1 is a mediator and therapeutic target in primary sclerosing cholangitis
J Hepatol. 2025;83(6):1305-1319
Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): A randomised, double-blind, multicentre, placebo-controlled, phase 3 trial
Lancet Gastroenterol Hepatol. 2026;11(1):46-58
Isolated IgG elevation in patients with persistently normal transaminases does not affect the outcome of autoimmune hepatitis
JHEP Rep. 2025;7(11):101562
Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): A randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
Lancet Gastroenterol Hepatol. 2026;11(1):22-33
Evaluating large language models’ performance in answering common questions on drug-induced liver injury
JHEP Rep. 2025;7(12):101579
Cannabidiol and liver enzyme level elevations in healthy adults: A randomized clinical trial
JAMA Intern Med. 2025;185(9):1070-1078
Intrahepatic donor microbiota-based metataxonomic signature detected in organ preservation solution enables prediction of short-term liver transplant outcomes
Gut. 2025;74(12):2058-2069
Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort study
Hepatology. 2025;82(5):1122-1137